Sildenafil side effects range from relatively common tolerability reactions such as headache, flushing and dyspepsia to uncommon but clinically important events addressed in warnings and post-marketing safety information. Their frequency cannot be represented by one universal percentage because sildenafil products, indications, doses and study populations differ.
In flexible-dose placebo-controlled erectile-dysfunction trials, headache was reported in 16% of sildenafil-treated participants versus 4% with placebo, flushing in 10% versus 1%, dyspepsia in 7% versus 2%, nasal congestion in 4% versus 2% and abnormal vision in 3% versus 0%. Fixed-dose trials also showed that several adverse reactions became more frequent at higher studied doses.
Serious safety topics require a different interpretation from common trial reactions. Current labeling addresses prolonged erection or priapism, sudden vision loss, sudden hearing decrease or loss, hypotension in relevant settings and cardiovascular safety. Some rare events were identified through post-marketing reports, where frequency and causal relationship cannot always be reliably established.
In prescribing information, adverse reactions are undesirable events for which the available evidence supports inclusion in the drug's safety profile. Clinical trials, post-marketing surveillance and other regulatory evidence contribute different kinds of information.
For sildenafil, common trial reactions are usually described with numerical frequencies, while rare post-marketing events often cannot be assigned a reliable incidence because they are reported voluntarily from a population of uncertain size.
Product context also matters. ED sildenafil is commonly studied as intermittent treatment, while REVATIO studies involve repeated treatment in patients with pulmonary arterial hypertension. Their percentages should not be combined as though they came from one population.
| Safety Term | Interpretation |
|---|---|
| Adverse reaction | Undesirable reaction included in the medicine's safety information |
| Clinical-trial frequency | Observed percentage under defined study conditions |
| Post-marketing report | Event reported after approval; frequency and causality may be uncertain |
| Warning / precaution | Important safety risk or circumstance addressed separately in labeling |
| Contraindication | Situation in which current labeling directs that sildenafil should not be used |
Flexible-dose ED trials provide a useful reference because they reflect the as-needed sildenafil regimen used in those studies. Among 734 sildenafil-treated participants and 725 placebo-treated participants, several adverse reactions occurred more frequently with sildenafil.
Headache was the most frequently reported reaction in this dataset, followed by flushing and dyspepsia. Nasal congestion and transient visual symptoms were less frequent but still occurred more often than with placebo.
These percentages belong to the specific ED clinical-trial dataset and should not be presented as universal probabilities for every sildenafil product, indication or individual.
| Adverse Reaction | Sildenafil | Placebo |
|---|---|---|
| Headache | 16% | 4% |
| Flushing | 10% | 1% |
| Dyspepsia | 7% | 2% |
| Nasal congestion | 4% | 2% |
| Abnormal vision | 3% | 0% |
| Back pain | 2% | 2% |
| Dizziness | 2% | 1% |
| Rash | 2% | 1% |
Adverse-reaction percentages only make sense when attached to the study population, product context and regimen from which they came. A percentage from ED trials should not be substituted directly for one from PAH studies.
Current REVATIO labeling illustrates the difference. In the SUPER-1 PAH trial, participants receiving 20 mg three times daily reported headache in 46% of cases versus 39% with placebo, dyspepsia in 13% versus 7%, flushing in 10% versus 4% and diarrhea in 9% versus 6%.
Those higher absolute percentages do not mean that one sildenafil indication is inherently more dangerous than another. PAH patients, treatment schedules, background illness and placebo-event rates differ substantially from the ED trial population.
Clinical-trial labels also caution that adverse-reaction rates from different studies cannot be directly compared and may not reflect rates observed in routine practice.
| Trial Context | Selected Reaction | Sildenafil | Placebo |
|---|---|---|---|
| ED flexible-dose trials | Headache | 16% | 4% |
| ED flexible-dose trials | Flushing | 10% | 1% |
| ED flexible-dose trials | Dyspepsia | 7% | 2% |
| REVATIO SUPER-1, 20 mg three times daily | Headache | 46% | 39% |
| REVATIO SUPER-1, 20 mg three times daily | Dyspepsia | 13% | 7% |
| REVATIO SUPER-1, 20 mg three times daily | Flushing | 10% | 4% |
| REVATIO SUPER-1, 20 mg three times daily | Diarrhea | 9% | 6% |
Serious sildenafil safety events should be separated from common tolerability effects because their frequency, evidence source and clinical significance differ.
Current labeling warns about prolonged erections and priapism, sudden loss of vision that may represent non-arteritic anterior ischemic optic neuropathy, and sudden decrease or loss of hearing. Sildenafil's vasodilatory properties can also contribute to clinically important hypotension in susceptible settings or interacting-drug contexts.
Serious cardiovascular, cerebrovascular and vascular events have also been reported post-marketing in temporal association with sildenafil. These reports should not be presented as proof that sildenafil caused each event because many affected individuals had cardiovascular risk factors and voluntary reports cannot establish incidence or causality reliably.
| Serious Safety Event | Label Context |
|---|---|
| Erection lasting more than 4 hours | Requires immediate medical assistance because untreated priapism can cause permanent tissue damage |
| Sudden vision loss | Can be a sign of NAION; current labeling directs patients to stop sildenafil and seek medical care |
| Sudden hearing decrease or loss | May occur with tinnitus or dizziness; current labeling directs prompt medical attention |
| Clinically significant hypotension | Can become more important with interacting vasodilators, alpha-blockers, antihypertensives or higher sildenafil exposure |
| Serious cardiovascular / cerebrovascular events | Reported post-marketing in temporal association; individual causal relationship is not established by the reports alone |
Current sildenafil labeling gives particularly clear action language for prolonged erection, sudden vision loss and sudden hearing changes.
An erection persisting longer than 4 hours requires immediate medical assistance. The label notes that delayed treatment of priapism can result in penile tissue damage and permanent loss of erectile function.
Sudden loss of vision in one or both eyes requires stopping sildenafil and seeking medical care. Sudden decrease or loss of hearing also requires stopping the PDE5 inhibitor and seeking prompt medical attention.
Other severe or rapidly worsening symptoms require clinical assessment according to the situation, but this page does not attempt to diagnose symptoms from a side-effect list.
| Situation | Current Label-Based Response |
|---|---|
| Erection lasting more than 4 hours | Seek immediate medical assistance |
| Sudden loss of vision in one or both eyes | Stop sildenafil and seek medical care |
| Sudden decrease or loss of hearing | Stop sildenafil and seek prompt medical attention |
| Severe or rapidly worsening symptoms | Require appropriate clinical assessment rather than self-diagnosis from a side-effect list |
Clinical trials and post-marketing surveillance answer different safety questions. Controlled trials allow adverse-event frequencies to be compared with placebo under defined conditions.
Post-marketing surveillance can identify uncommon or delayed events that were not characterized well in pre-approval studies, but voluntary reporting has important limitations. The size and exposure of the underlying population are uncertain, reporting is incomplete and medical details can be limited.
For that reason, current labeling explicitly states that post-marketing frequencies cannot always be reliably estimated and that causal relationships to sildenafil exposure cannot always be established.
A rare post-marketing report should therefore not be presented as though it had the same evidentiary meaning as a reaction occurring at a measured frequency in a randomized controlled trial.
| Evidence Source | What It Can Show | Important Limitation |
|---|---|---|
| Placebo-controlled clinical trial | Measured reaction frequency under defined study conditions | Study population may differ from routine practice |
| Open-label extension | Longer-duration safety experience | No equivalent blinded placebo comparison |
| Post-marketing surveillance | Signals and uncommon events after widespread use | Frequency usually cannot be calculated reliably |
| Spontaneous case report | Temporal association in an individual report | Does not alone establish causation |
| Product labeling | Integrates available regulatory safety evidence | Must still be interpreted by product and indication context |
Sildenafil visual safety has two distinct layers: relatively common transient visual disturbances seen in controlled ED trials and rare serious ocular events described in warnings and post-marketing information.
In flexible-dose ED trials, abnormal vision was reported in 3% of sildenafil-treated participants and 0% of placebo participants. Labeling describes these reactions as generally mild and transient, predominantly a color tinge to vision but also increased sensitivity to light or blurred vision.
Fixed-dose trials show a clear exposure-related signal: abnormal vision was reported in 1% at 25 mg, 2% at 50 mg and 11% at 100 mg, compared with 1% with placebo.
Sudden vision loss is different from these transient effects. NAION has been reported rarely in temporal association with PDE5 inhibitors, but current labeling states that the available reports cannot establish that sildenafil directly caused every event.
| Visual Safety Finding | Observed Context |
|---|---|
| Abnormal vision — flexible-dose ED trials | 3% sildenafil vs 0% placebo |
| Abnormal vision — 25 mg fixed dose | 1% |
| Abnormal vision — 50 mg fixed dose | 2% |
| Abnormal vision — 100 mg fixed dose | 11% |
| Typical trial description | Transient color tinge, increased light sensitivity or blurred vision |
| Sudden vision loss / NAION | Rare serious post-marketing safety concern requiring medical attention |
Sildenafil has systemic vasodilatory properties and can transiently lower blood pressure. This pharmacodynamic effect is distinct from the common adverse reaction of flushing but helps explain why cardiovascular context and interacting vasodilators matter.
In healthy-volunteer labeling, a 100 mg oral dose produced a mean maximum decrease in sitting or supine blood pressure of roughly 8/5 mmHg. The clinical importance can be greater in individuals who are particularly sensitive to vasodilation or when sildenafil is combined with other blood-pressure-lowering medicines.
Post-marketing reports have included myocardial infarction, sudden cardiac death, arrhythmias and cerebrovascular events in temporal association with sildenafil use. Such reports do not establish that sildenafil caused the event in each case, especially because underlying cardiovascular disease and sexual activity can independently contribute to risk.
The broader cardiovascular framework belongs on the sildenafil warnings page, while formal restrictions and interacting medicines are covered separately.
| Topic | Dedicated Resource |
|---|---|
| Warnings and cardiovascular precautions | Sildenafil Warnings & Precautions |
| Formal contraindications | Sildenafil Contraindications |
| Drug interactions | Sildenafil Drug Interactions |
| Nitrate interaction | Sildenafil and Nitrates Interaction |
| Riociguat interaction | Sildenafil and Riociguat Interaction |
Headache and flushing are among the most characteristic common sildenafil adverse reactions and are consistent with the drug's vascular pharmacology.
In flexible-dose ED trials, headache occurred in 16% of sildenafil-treated participants versus 4% with placebo, while flushing occurred in 10% versus 1%.
Fixed-dose studies also demonstrate that adverse-reaction frequency can depend on dose. Headache was reported in 16%, 21% and 28% of participants receiving 25 mg, 50 mg and 100 mg respectively, compared with 7% on placebo.
Flushing was reported in 10%, 19% and 18% across the same fixed-dose groups versus 2% with placebo. This pattern supports a dose-related tendency for some reactions but does not mean every adverse effect rises linearly with dose.
| Reaction | 25 mg | 50 mg | 100 mg | Placebo |
|---|---|---|---|---|
| Headache | 16% | 21% | 28% | 7% |
| Flushing | 10% | 19% | 18% | 2% |
Dyspepsia is the most prominent gastrointestinal adverse reaction in ED sildenafil trial labeling. In flexible-dose studies it occurred in 7% of sildenafil-treated participants versus 2% with placebo.
Fixed-dose data again show a dose-related pattern: dyspepsia was reported in 3% at 25 mg, 9% at 50 mg and 17% at 100 mg, compared with 2% with placebo.
Nausea occurred in 2% to 3% across fixed-dose sildenafil groups versus 1% with placebo. In the PAH SUPER-1 trial, diarrhea and dyspepsia were also among common REVATIO adverse reactions, illustrating how the observed safety profile depends on treatment context and population.
| Digestive Reaction / Context | Observed Frequency |
|---|---|
| Dyspepsia — ED flexible-dose sildenafil | 7% vs 2% placebo |
| Dyspepsia — 25 mg fixed dose | 3% |
| Dyspepsia — 50 mg fixed dose | 9% |
| Dyspepsia — 100 mg fixed dose | 17% |
| Nausea — fixed-dose sildenafil | 2–3% vs 1% placebo |
| Dyspepsia — REVATIO 20 mg TID SUPER-1 | 13% vs 7% placebo |
| Diarrhea — REVATIO 20 mg TID SUPER-1 | 9% vs 6% placebo |
Side effects, warnings and contraindications are related safety concepts but they are not interchangeable regulatory categories.
An adverse reaction describes an undesirable response associated with medicine use. A warning or precaution identifies an important risk or circumstance that requires specific attention. A contraindication identifies a situation in which current labeling directs against sildenafil use.
For example, headache is a common adverse reaction, prolonged erection is addressed as a serious warning, and concomitant nitrate or riociguat use is a formal contraindication.
Keeping these categories separate prevents serious restrictions from being diluted into an ordinary side-effect list and prevents common adverse reactions from being described as contraindications.
| Safety Concept | Sildenafil Example |
|---|---|
| Common adverse reaction | Headache or flushing |
| Serious warning | Prolonged erection, sudden vision loss or sudden hearing loss |
| Interaction warning / precaution | Potential additional hypotension with alpha-blockers or antihypertensives |
| Contraindication | Organic nitrates / nitrites or riociguat |
| Detailed warnings | Sildenafil Warnings & Precautions |
| Detailed contraindications | Sildenafil Contraindications |
A side effect can occur during sildenafil use without another medicine being involved, while a drug interaction arises because another substance changes sildenafil exposure or adds to a pharmacodynamic effect.
The distinction can overlap clinically. Strong CYP3A inhibition can increase sildenafil exposure and make exposure-related reactions such as hypotension, syncope or prolonged erection more relevant, while nitrates and riociguat create contraindicated pharmacodynamic combinations.
Food can modify sildenafil pharmacokinetics but is not itself classified as a sildenafil adverse reaction. Those mechanisms belong on their dedicated interaction and food-effect pages.
| Topic | Dedicated Page |
|---|---|
| Drug interactions | Sildenafil Drug Interactions |
| CYP3A4 interactions | Sildenafil and CYP3A4 |
| Nitrate interaction | Sildenafil and Nitrates Interaction |
| Riociguat interaction | Sildenafil and Riociguat Interaction |
| Food effects | Sildenafil Food Effects |
Individual tolerability can differ because the same administered product can produce different systemic exposure and different physiological responses across people.
Age, severe renal impairment, hepatic impairment and CYP3A inhibitors can increase sildenafil exposure in documented PK studies. Higher exposure does not guarantee that a particular adverse reaction will occur, but it can change the safety context.
Other factors operate pharmacodynamically rather than through concentration alone. Concurrent antihypertensives can add to blood-pressure lowering, while underlying cardiovascular or ocular risk can change the significance of particular safety events.
These observations explain population-level variability; they should not be used to predict an individual's side-effect probability from a PK percentage alone. The exposure component is covered further on the sildenafil PK variability page.
| Factor | Possible Safety Relevance |
|---|---|
| Higher systemic exposure | Can increase the importance of exposure-related adverse reactions |
| Strong CYP3A inhibition | Can substantially increase sildenafil exposure |
| Severe renal impairment | Parent AUC and Cmax are approximately doubled in label PK data |
| Hepatic impairment | Can substantially increase sildenafil exposure |
| Older age | Associated with higher total sildenafil exposure in PK studies |
| Other blood-pressure-lowering medicines | Can increase pharmacodynamic hypotension risk |
| Underlying risk factors | Can affect the interpretation of cardiovascular, ocular or other safety events |
| PK variability | Sildenafil PK Variability |
In flexible-dose placebo-controlled ED trials, the most prominent reactions included headache at 16% versus 4% with placebo, flushing at 10% versus 1%, dyspepsia at 7% versus 2%, nasal congestion at 4% versus 2% and abnormal vision at 3% versus 0%. These percentages belong to that specific trial context and are not universal rates for every sildenafil product.
Some did in fixed-dose ED trials. For example, headache was reported in 16%, 21% and 28% of participants receiving 25 mg, 50 mg and 100 mg respectively, while dyspepsia occurred in 3%, 9% and 17%. Not every adverse reaction showed a simple linear dose relationship.
Controlled ED trials reported transient abnormal vision, usually a color tinge, increased sensitivity to light or blurred vision. Sudden vision loss is a different and much more serious safety event that may represent NAION and requires medical attention.
Current labeling directs immediate medical assistance for an erection lasting longer than 4 hours, medical care for sudden loss of vision in one or both eyes, and prompt medical attention for sudden decrease or loss of hearing.
No. Post-marketing reports are important for identifying safety signals, but they come from populations of uncertain size and can contain limited clinical information. Their frequency and causal relationship to sildenafil cannot always be reliably established.
No. ED and PAH studies involve different populations, dosing patterns and placebo-event rates, so their adverse-reaction percentages should not be compared directly. Current REVATIO PAH trials, for example, report a different frequency pattern from flexible-dose ED trials.